1 研究業績

(書籍)

1) 和田郁人, 山本剛史, 斯波真理子, 高コレステロール血症に対する核酸医薬の

開発, 監修 和田猛, 核酸医薬の創製と応用展開, シーエムシー出版, 270-278,

2016.2

2) 小倉正恒, 斯波真理子, 家族性高コレステロール血症ホモ接合体 , 編集責任

尾崎承一, 難病事典, 学研, 387-390, 2015.12

3) 斯波真理子, 脂質異常症, 総編集 金澤一郎, 永井良三, 今日の診断指針 第 7

版, 医学書院, 121-124, 2015

4) Shibata MA, Morimoto J, Shibata E, Harada-Shiba M, Fujioka S, Inhibition of Tumor

Growth and Metastasis by a Combination of Anti-VEGF-C and Enhance

5) d IL-12 Therapy in an Immunocompetent Mouse Mammary Cancer Model, edited by

Gunduz E and Gunduz M, Breast Cancer-Current and Alternative Therapeutic

Modalities, In Tech, 489-502, November 2011

6) Iwamoto N, Harada-Shiba M, Intratracheal Gene Transfer Using Polyplex

Nanomicelles and Their Application to Cardiology, Nanomedicine and the

Cardiovascular System, edited by Ross J. Hunter,Victor R. Preedy, Nanomedicine

and the Cardiovascular System, Science Publishers, 284-302, 2011

7) Harada-Shiba M, edited by Taira K, Kataoka K, Niidome T, Non-Viral Gene Therapy,

Springer-Verlag, Gene Transfer and Target Disease, 246-260,2005

論文

（欧文）

1) Wada S, Yasuhara H, Wada F, Sawamura M, Waki R, Yamamoto T, Harada-Shiba

M, Obika S: Evaluation of the effects of chemically different linkers on hepatic

accumulations, cell tropism and gene silencing ability of cholesterol-conjugated

antisense oligonucleotides, J Controlled Release, in press

2) Yamamoto T, Sawamura M, Wada F, Harada-Shiba M, Obika S: Serial

incorporation of a monovalent GalNAc phosphoramidite unit into

hepatocyte-targeting antisense oligonucleotides, Bioorg Med Chem, 24(1): 26-32,

2016.1

3) Ogura M, Hori M, Harada-Shiba M: Association between cholesterol efflux

capacity and atherosclerotic cardiovascular disease patients with familial

hypercholesterolemia, Arteriosclr Thromb Vasc Biol, 36: 181-188, 2016.1

4) Miyagi Y, Harada-Shiba M, Ohta T: Effect of statin therapy in 4-year-old

dichorionic diamniotic twin with familial hypercholesterolemia showing multiple

xanthomas, J Atheroscler Thromb, 23(1): 112-117, 2016.1

5) Harada-Shiba M, Arisaka O, Ohtake A, Okada T, Suganami H, NK-104-PH01

study registration group : Efficacy and Safety of Pitavastatin in Japanese Male

Children with Familial Hypercholesterolemia. J Atheroscler Thromb, 23(1): 48-55,

2016.1

6) Vallejo-Vaz A J, Kondapally Seshasai S R, Cole D, Hovingh G.K, Kastelein J J.P,

Mate P, Raal F J, Santos R D, Soran H, Watts G F, Abifadel M, Aguilar-Salinas C

A,Akram A, Alnouri F, Alonsa R, Al-Rasadi K, Banace M, Bogsrud M P, Bourbon

M, Bruckert E, Car J, Corral P, Descamps O, Dieplinger H, Durst R, Freiberger T,

Gaspar I M, Genest J, Harada-Shiba M, Jiang L, Kayikcioglu M, Lam Carolyn,

Latkovskis G, Laufs Ulrich, Liberopoulos E, Nilsson L, Nordestgaard B G,

O’Donoghue J M, Sahebkar A, Schunkert H, Shehab A, Stoll M, Su T-C, Susekov

A, Widen E, Catapano A L, Ray K K: Familial hypercholesteroleamia: A global call

to arms, Atherosclerosis, 243(1): 257-259, 2015.11

7) Hopkins PN, Defesche J, Fouchier SW, Bruckert E, Luc G, Cariou B, Sjouke B,

Leren TP, Harada-Shiba M, Mabuchi H, Rabes JP, Carrie A, van Heyningen C,

Carreau V, Farnier M, Teoh Y P, Bourbon M, Kawashiri MA, Nohara A, Soran H,

Marais AD, Tada H, Abifadel M, Boileau C, Chanu B, Katsuda S, Kishimoto I,

Lambert G, Makino H, Miyamoto Y, Pichelin M, Yagi K, Yamagishi M, Zair Y,

Mellis S, Yancopoulos GD, Stahl N, Mendoza J, Du Y, Hamon S, Krempf M,

Swergold GD: Characterization of Autosomal Dominant Hypercholesterolemia

Caused by PCSK9 Gain of Function Mutations and its Specific Treatment with

Alirocumab, a PCSK9 Monoclonal Antibody. Circ Cardiovasc Genet, 8(6):

823-831, 2015.12

8) Shibata MA, Kusakabe M, Shibata E, Morimoto J, Fujioka S, Harada-Shiba M,

Iinuma M: Treatment with Tenascin C Antibody and/or α-Mangostin Reduces

Tumor Growth and Lymph Node Metastasis in a Model of Metastatic Mammary

Cancer. BAOJ Cancer Res Ther, an open access journal, Volume1;Issue 3; 011:

1-13, 2015.

9) Stefanutti C, D'Alessandri G, Petta A, Harada-Shiba M, Julius U, Soran H,

Moriarty PM, Romeo S, Drogari E, Jaeger BR; MightyMedic (Multidisciplinary

International Group for Hemapheresis TherapY and MEtabolic DIsturbances

Contrast) Working Group: First on-line survey of an international multidisciplinary

working group (MightyMedic) on current practice in diagnosis, therapy and

follow-up of dyslipidemias, Atheroscler Suppl, 18: 241-250, 2015.4

10) Yamamoto Y, Yahara A, Waki R, Yasuhara H, Wada F, Harada-Shiba M, Obika S:

Amido-bridged nucleic acids with small hydrophobic residues enhance hepatic

tropism of antisense oligonucleotides in vivo. Organic & Bionolecular Chemistry,

13(12): 3757-3765, 2015.3

11) Pang J, Sullivan D R, Harada-Shiba M, YA Ding P, Selvey S, Ail S, Watts G F:

Significant Gaps in Awareness of Familial Hypercholesterolaemia among

Physicians in selected Asia-Pacific Countries: a Pilot Study. Journal of Clinical

Lipidology, 9(1): 42-48, 2015.1

12) Hori M, Ishihara M, Yuasa Y, Makino H, Yanagi K, Tamanaha T, Kishimoto I,

Kujiraoka T, Hattori H, Harada-Shiba M: Removal of plasma mature and

furin-cleaved proprotein convertase subtilisin/kexin 9 (pcsk9) by low-density

lipoprotein-apheresis in familial hypercholesterolemia: Development and

application of a new assay for pcsk9. J. Clin. Endocrinol. Metab. 100(1): E41-49,

2015:jc20143066

13) Ohshima M, Taguchi A, Tsuda H, Sato Y, Yamahara K, Harada-Shiba M, Miyazato

M, Ikeda T, Iida H, Tsuji M: Intraperitoneal and intravenous deliveries are not

comparable in terms of drug efficacy and cell distribution in neonatal mice with

hypoxia-ischemia. Brain Dev. 37(4): 376-386, 2015.4

14) Yamamoto T, Fujii N, Yasuhara H, Wada S, Wada F, Shigesada N, Harada-Shiba M,

Obika S: Evaluation of multiple-turnover capability of locked nucleic acid

antisense oligonucleotides in cell-free rnase h-mediated antisense reaction and in

mice. Nucleic acid therapeutics. 24: 283-290, 2014.8

15) Yamahara K, Harada K, Ohshima M, Ishikane S, Ohnishi S, Tsuda H, Otani K,

Taguchi A, Soma T, Ogawa H, Katsuragi S, Yoshimatsu J, Harada-Shiba M,

Kangawa K, Ikeda T: Comparison of angiogenic, cytoprotective, and

immunosuppressive properties of human amnion- and chorion-derived

mesenchymal stem cells. PLoS One. 9:e88319, 2014.2

16) Tachibana Y, Munisso MC, Kamata W, Kitagwa M, Harada-Shiba M, Yamaoka T:

Quick nuclear transportation of sirna and in vivo hepatic apob gene silencing with

galactose-bearing polymeric carrier. J. Biotechnol. 175: 15-21, 2014.4

17) Tsuji M, Taguchi A, Ohshima M, Kasahara Y, Sato Y, Tsuda H, Otani K, Yamahara

K, Ihara M, Harada-Shiba M, Ikeda T, Matsuyama T: Effects of intravenous

administration of umbilical cord blood CD34+ cells in a mouse model of neonatal

stroke. NeuroScience, 263C: 148-158, 2014.3

18) Yamamoto T, Obika S, Nakatani M, Yasuhara H, Wada F, Shibata E, Shibata MA,

Harada-Shiba M: Locked nucleic acid antisense inhibitor targeting apolipoprotein

C-III efficiently and preferentially removed triglyceride from large VLDL particles

from murine plasma. European Journal of Pharmacology, 723: 353-359, 2014.1

19) Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, Egusa G, Hiro T,

Hirobe K, Iida M, Kihara S, Kinoshita M, Maruyama C, Ohta T, Okamura T,

Yamashita S, Yokode M, Yokote K, Harada-Shiba M, Arai H, Bujo H, Nohara A,

Oikawa S, Okada T, Wakatsuki A: Familial hypercholesterolemia. J Atheroscler

Thromb, 21: 6-10, 2014.

20) Nagasaki Y, Yamazaki T, Kikuchi A, Harada-Shiba M: Elevated atherogenic

indexfollowing oral administration of quaternized polyamine nanogels. Colloids

and Surfaces. B, Biointerfaces, 113: 237-242, 2014.

21) Yuasa Y, Osaki T, Makino H, Iwamoto N, Kishimoto I, Usami M, Harada-Shiba M:

Proteomic analysis of proteins eliminated by LDL-apheresis. Ther Apher Dial,

18(1): 93-102, 2014.

22) Yokoyama S, Ueshima H, Miida T, Nakamura M, Takata K, Fukukawa T, Goto T,

Harada-Shiba M, Sano M, Kato K, Matsuda K: High-density lipoprotein levels

have markedly increased over the past twenty years in japan. J Atheroscler

Thromb, 21(2): 151-160, 2014.

23) Shibata MA, Shibata E, Morimoto J, Harada-Shiba M: Therapy with siRNA for

Vegf-c but Not for Vegf-d Suppresses Wide-spectrum Organ Metastasis in an

Immunocompetent Xenograft Model of Metastatic Mammary Cancer. Anticancer

Research, 33: 4237-4248, 2013.

24) Kobayashi K, Nagata E, Sasaki K, Harada-Shiba M, Kojo S, Kikuzaki H: Increase

in Secretory Sphingomyelinase Activity and Specific Ceramides in the Aorta of

Apolipoprotein E Knockout Mice during Aging. Biol. Pharm. Bull, 36(7):

1192-1196, 2013.

25) Makino H, Harada-Shiba M: New aspects of statin therapy. IEMAMC, 13: 97-106,

2013.

26) Terasaki F, Morita H, Harada-Shiba M, Ohta N, Otsuka K, Nogi S, Miyamura M,

Suzuki S, Ito T, Shimomura H, Katsumata T, Miyamoto Y, Ishizaka N: Familial

Hypercholesterolemia with Multiple Large Tendinous Xanthomas and Advanced

coronary Artery Atherosclerosis. Intern Med, 52: 577-581, 2013.

27) Kang JH, Tachibana Y, Obika S, Harada-Shiba M, Yamaoka T: Efficient reduction

of serum cholesterol by combining a liver-targeted gene delivery system with

chemically modified apolipoprotein B siRNA. J Control Release, 163(2): 119-124,

2012.9

28) Yamamoto T, Yasuhara H, Wada F, Harada-Shiba M, Imanishi T, Obika S: Superior

silencing by 2’,4’-BNANC-based short antisense oligonucleotides compared to

2’,4’-BNA/LNA-based apolipoprotein B antisense inhibitors. J Nucleic Acids,

707323, 2012.

29) Harada-Shiba M, Arai H, Oikawa S, Ohta T, Okada T, Okamura T, Nohara A, Bujo

H, Yokote K, Wakatsuki A, Ishibashi S, Yamashita S: Guidelines for the

management of familial hypercholesterolemia. J Atheroscler Thromb, 19(12):

1043-1060, 2012.

30) Harada-Shiba M, Arai H, Okamura T, Yokote K, Oikawa S, Nohara A, Okada T,

Ohta T, Bujo H, Watanabe M, Wakatsuki A, Yamashita S: Multicenter study to

determine the diagnosis criteria of heterozygous familial hypercholesterolemia in

Japan. J Atheroscler Thromb, 19(11): 1019-1026, 2012.

31) Wada S, Obika S, Shibata MA, Yamamoto T, Nakatani M, Yamaoka T, Torigoe H,

Harada-Shiba M: Development of a 2’,4’-BNA/LNA based siRNA for dyslipidemia and

assessment of the effects of its chemical modifications in vivo. Molecular Therapy -

Nucleic Acids, 1, e45: 1-15, 2012.

32) Yamamoto T, Harada-Shiba M, Nakatani M, Wada S, Yasuhara H, Narukawa K,

Sasaki K, Shibata MA, Torigoe H, Yamaoka T, Imanishi T, Obika S:

Cholesterol-Lowering Action of BNA-based Antisense Oligonucleotides Targeting

PCSK9 in Atherogenic Diet-Induced Hypercholesterolemic Mice. Molecular

Therapy- Nucleic Acid, 1, e22: 1-11, 2012.

33) Uchida S, Itaka K, Chen Q, Osada K, Ishii T, Shibata MA, Harada-Shiba M,

Kataoka K: PEGylated polyplex with optimized PEG shielding enhances gene

introduction in lungs by minimizing inflammatory responses. Mol Ther, 20(6):

1196-1203, 2012.6

34) Sugisawa T, Okamura T, Makino H, Watanabe M, Kishimoto I, Miyamoto Y,

Iwamoto N, Yamamoto A, Yokoyama S, Harada-Shiba M: Defining patients at

extremely high risk for coronary artery disease in heterozygous familial

hypercholesterolemia. J Atheroscler Thromb, 19(4) : 369-375, 2012.4

35) Yokoyama S, Yamashita S, Ishibashi S, Sone H, Oikawa S, Shirai K, Ohta T, Bujo

H, Kobayashi J, Arai H, Harada-Shiba M, Eto M, Hayashi T, Gotoda T, Suzuki H,

Yamada N: Background to discuss guidelines for control of plasma

HDL-cholesterol in Japan. J Atheroscler Thromb, 19(3): 207-212, 2012.3

36) Gotoda T, Shirai K, Ohta T, Kobayashi J, Yokoyama S, Oikawa S, Bujo H,

Ishibashi S, Arai H, Yamashita S, Harada-Shiba M, Eto M, Hayashi T, Sone H,

Suzuki H, Yamada N: Diagnosis and management of type Ⅰ and type V

hyperlipoproteinemia. J Atheroscler Thromb, 19: 1-12, 2012.

37) Arai H, Ishibashi S, Bujo H, Hayashi T, Yokoyama S, Oikawa S, Kobayashi J,

Shirai K, Ota T, Yamashita S, Gotoda T, Harada-Shiba M, Sone H, Eto M, Suzuki

H, Yamada N: Management of type IIb dyslipidemia. J Atheroscler Thromb, 19:

105-114, 2012.

38) Fujikura J, Nakao K, Sone M, Noguchi M, Mori E, Naito M, Taura D,

Harada-Shiba M, Kishimoto I, Watanabe A, Asaka I, Hosoda K: Induced

pluripotent stem cells generated from diabetic patients with mitochondrial DNA

A3243G mutation. Diabetologia, 55: 1689-1698. 2012.

39) Uchida S, Itaka K, Chen Q, Osada K, Miyata K, Ishii T, Harada-Shiba M, Kataoka

K: Combination of chondroitin sulfate and polyplex micelles from Poly(ethylene

glycol)-poly{N'-[N-(2-aminoethyl)-2-aminoethyl]aspartamide} block copolymer

for prolonged in vivo gene transfection with reduced toxicity: J Control Release,

155(2): 296-302. 2011.10.

40) Harada K, Miyamoto Y, Morisaki H, Ohta N, Yamanaka I, Kokubo Y, Makino H,

Harada-Shiba M, Okayama A, Tomoike H, Okamura T, Saito Y, Yoshimasa Y,

Morisaki T: A novel Thr56Met mutation of the autosomal recessive

hypercholesterolemia gene associated with hypercholesterolemia. J Atheroscler

Thromb, 17(2): 131-140, 2010.

41) Kang J, Tachibana Y, Kanata W, Mahara A, Harada-Shiba M, Yamaoka T :

Liver-targeted siRNA delivery by polyethyleneimine(PEI)-pullulan carrir. Bioorg

Med Chem, 18: 3946-3950, 2010.

42) Fujita Y, Kakino A, Harada-Shiba M, Sato Y, Otsui K, Yoshimoto R, Sawamura T:

C-Reactive protein uptake by macrophage cell line via Class-A scavenger receptor.

Clin Chem, 56(3): 478-481, 2010.

43) Harada-Shiba M, Sugisawa T, Makino H, Abe M, Tsushima M, Yoshimasa Y,

Yamashita T, Miyamoto Y, Yamamoto A, Tomoike H, Yokoyama S: Impact of statin

treatment on the clinical fate of heterozygous familial hypercholesterolemia. J

Atheroscler Throm, 17(7): 667-674, 2010.

44) Harada-Shiba M, Takamisawa I, Miyata K, Ishii T, Nishiyama N, Itaka K,

Kangawa K, Yoshihara F, Asada Y, Hatakeyama K, Nagaya N, Kataoka K:

Intratracheal gene transfer of adrenomedullin using polyplex nanomicelles

attenuates monocrotaline-induced pulmonary hypertension in rats. Mol ther, 17(7):

1180-1186, 2009.

45) Watanabe K, Harada-Shiba M, Suzuki A, Gokuden R, Kurihara R, Sugao Y, Mori T,

Katayama Y, Niidome T: In vivo siRNA delivery with dendritic poly(L-lysine) for

the treatment of hypercholesterolemia. Mol Biosystems, 5: 1306-1310, 2009.

46) Shimano H, Arai H, Harada-Shiba M, Ueshima H, Ohta T, Yamashita S, Gotoda T,

Kiyohara Y, Hayashi T, Kobayashi J, Shimamoto K, Bujo H, Ishibashi S, Shirai K,

Oikawa S, Saito Y, Yamada N: Proposed guidelines for hypertriglyceridemia in

japan with non-HDL cholesterol as the second target. J Atheroscler Thromb,

15(3): 116-121, 2008.

47) Yamashita S, Bujyo H, Ari H, Harada-Shiba M, Matsui S, Fukushima M, Saito Y,

Kita T, Matsuzawa Y: Long-term probucol treatment prevents secondary

cardiovascular events : a cohort study of patients with heterozygous familial

hypercholesterolemia in Japan. J Atheroscler Throm, 15, 6: 292-303, 2008.

48) Makino H, Harada-Shiba M: Safety Aspects of Statins: Which Factors Create the

Adverse Effects of Statins: Immum. Endoc.&Metab.Agents in Med.Chem, 8(2):

172-176, 2008.

49) Ichi I , Takashima Y , Adachi N , Nakahara K , Kamikawa C , Harada – Shiba M ,

Kojo S : Effects of Dietary Cholesterol on Tissue Ceramides and Oxidation

products of Apolipoprotein B-100 in ApoE-Deficient Mice. Lipids, 42(10):

893-900, 2007.

50) Jo J, Nagaya N, Miyahata Y, Kataoka M, Harada-shiba M, Kangawa K, Tabata Y:

Transplantation of genetically engineered mesenchymal stem cells improves

cardiac function in rats with myocardial infarction: benefit of a novel nonviral

vector, cationized dextran. Tissue Eng, 13(2): 31, 2007.

51) Ichi I, Nakahara K, Miyashita Y, Hidaka A, Kutsukake S, Inoue K, Maruyama T,

Miwa Y, Harada-Shiba M, Tsushima M, Kojo S: Kisei Cohort Study Group:

Association of ceramides in human plasma with risk factors of atherosclerosis.

Lipids, 41(9): 859-863, 2006.

52) Yamamoto A, Harada-Shiba M, Endo M, Kusakabe N, Tanioka T, Kato H, Shoji T:

The effect of ezetimibe on serum lipids and lipoproteins in patients with

homozygous familial hypercholesterolemia undergoing LDL-apheresis therapy.

Atherosclerosis, 186(1): 126-131, 2006.

53) Umeda M, Harada-Shiba M, Uchida K, Nakayama Y: Photo-control of the

polyplexen formation between DNA and photo-cation generatable water-soluble

polymers. Curr Drug Deliv. 2:207-214, 2005.

54) Nakayama Y, Masuda T, Nagaishi M, Hayashi M, Ohira M, Harada-Shiba M: High

performance gene delivery polymeric vector: Nano-Structured cationic star

polymers(star vectors). Curr Drug Deliv, 2: 53-57, 2005.

55) Harada-Shiba M, Takagi A, Marutsuka K, Moriguchi S, Yagyu H, Ishibashi S,

Asada Y, Yokoyama S: Disruption of autosomal recessive hypercholesterolemia

gene shows different phenotype in vitro and in vivo. Cird Res, 95(9): 945-952,

2004.

56) Tokunaga N, Nagaya N, Shirai M, Tanaka E, Ishibashi-Ueda H, Harada-Shiba M,

Kanda M, Ito T, Shimizu W, Tabata Y, Uematsu M, Nishigami K, Sano S, Kangawa

K, Mori H: Adrenomedullin gene transfer induces therapeutic angiogenesis in a

rabbit model of chronic hind limb ischemia : Benefits of a novel nonviral

vector,gelatin . Circulation, 109: 526-531, 2004.

57) Saito M, Tada Y, Harada-Shiba M, Yamamoto A, Kusakabe N, Yokogawa M,

Kodama H, Asada H, Miyagawa S: Homozygous familial hypercholesterolaemia :

development of xanthogranuloma in a boy at puberty under log – term low –

density lipoprotein apheresis and drug therapy. Br J Dermatol, 149: 1292-1308,

2003.

58) Makino H, Harada-Shiba M: Long-term effect of low density lipoprotein apheresis

in patients with homozylous familial hypercholesterolemia. Ther Apher Dial. 7:

397-401, 2003.

59) Nagaya N, Kangawa K, Kanda M, Uematsu M, Horio T, Fukuyama N, Hino J,

Harada-Shiba M, Okumura H, Tabata Y, Mochizuki N, Chiba Y, Nishioka K,

Miyatake K, Ashihara T, Hara H, Mori H: Hybrid cell-gene therapy for pulmonary

hypertension based on phagocytosing action of endothelial progenitor cells.

Circulation, 108: 889-895, 2003.

60) Harada-Shiba M, Takagi A, Miyamoto Y, Tsushima M, Ikeda Y, Yokoyama S,

Yamamoto A: Clinical features and genetic analisis of autosomal recessive

hypercholesterolemia. J Clin Endocrinol Metab June, 88(6): 2541-2547, 2003.

61) Harada-Shiba M, Yamauchi K, Harada A, Takamisawa I, Shimokado K, Kataoka

K: Polyion complex micelles as vectors in gene therapy－Pharmacokinetics and in

vivo gene transfer. Gene Therapy, 9: 407-414, 2002.

62) Yamamoto A, Harada-Shiba M, Kawaguchi A, Tsushima M: Apheresis technology

for prevention and regression of atherosclerosis. Therapeutic Apheresis, 5(4):

221-225, 2001.

63) Croniger C M, Millward C, Yang J, Kawai Y, Arinze I J, Liu S, Harada-Shiba M,

Chakravarty K K, Friedman J E, Poli V, Hanson R W: Mice with a deletion in the

gane for CCAAT/enhancer – binding protein beta have an attenuated response to

cAMP and impaired calbohydrate metabolism. Issue of January, 276(1): 629-638,

2001.

64) Sugano R, Yamamura T, Harada-Shiba M, Miyake Y, Yamamoto A: Uptake of

oxidized low–density lipoplotein in a THP – 1 cell line lacking scavenger receptor

A. Atherosclerosis, 158: 351-357, 2001.

65) Yamamoto A, Harada-Shiba M, Kawaguchi A, Oi K, Kubo H, Sakai S, Mikami Y,

Imai T, Ito T, Kato H, Endo M, Sato I, Suzuki Y, Hori H: The effect of atorvastatin

on serum lipids and lipoproteins in patients with homozygous familial

hypercholesterolemia undergoing LDL- apheresis therapy. Atherosclerosis, 153:

89-98, 2000.

66) Liu S, Croniger C, Arizmendi C, Harada-Shiba M, Ren J, Poli V, Hanson R W,

Friedman J E: Hypoglycemia and impaired hepatic glucose production in mice

with a deletion of the C / EBP β gene. J Clin Invest , 103: 207-213, 1999.

67) Harada-Shiba M, Kinoshita M, Kamido H, Shimokanido K: Oxidized low density

lipoprotein induces apoptosis in cultured human umbilical vein endothelial cells by

common and unique mechanisms. J Biol Chem, 273(16): 9681-9687, 1998.

68) Nishimura N, Harada-Shiba M, Tajima S, Sugano R, Yamamura T, Qiang Q Z,

Yamamoto A: Acquisition of secretion of transforming growth factor – β 1 leads

to autonomous suppession of scavenger receptor activity in a

monocyte–macrophage cell line, THP-1. J Biol Chem, 73: 1562-1567, 1998.

69) Mamo JC, Smith D, Yu KC, Kawaguchi A, Harada-Shiba M, Yamamura T,

Yamamoto A: Accumulation of chylomicron remnants in homozygous subjects

with familial hypelcholesterolaemia. Eur J Invest, 28: 379-384, 1998.

70) Yu KC, Smith D, yamamoto A, Kawaguchi A, Harada-Shiba M, Yamamura T,

Mamo JC: Phagocytic degradation of chylomicron remnants by fibroblasts from

subjects with homozygous familial hypercholesterolaemia. Clin Sci (Colch), 92:

197-203, 1997.

71) Harada-Shiba M, Yamamura T, Toyota Y, Tsushima M, Kojima S, Yamamoto A:

Kinetic analysis of cholesterol and Lp(a) using the rebound curve after

LDL–apheresis. Jpn J Apheresis, 15: 96-97, 1996.

72) Yamamoto A, Kojima S, Harada-Shiba M, Toyota Y, Takamiya M, Tsushima M,

Kishino B, Koga N, Tatami R: Plasmapheresis for prevention and regression of

coronary atherosclerosis. Ann NY Acad Sci, 748: 429-440, 1995.

73) Maruyama T, Miyake Y, Tajima S, Harada-Shiba M, Yamamura T, Tsushima M,

Kishino B, Horiguchi Y, Funahashi T, Matsuzawa Y, Yamamoto A: Common

mutations in the low-density-lipoprotein-receptor gene causing

familialhypercholesterolemia in the Japanese population. Arterioscler Thromb

Vasc Biol , 15: 1713-1718, 1995.

74) Kokawa T, Abumiya T, Kimura T, Harada-Shiba M, Koh H, Tsushima M,

Yamamoto A, Kato H: Tissue factor pathway inhibitor activity in human plasma.

Measurement of lipoprotein–associated and free forms in hyperlipidem.

Arteriosclea Thromb Vasc Biol , 15: 504 – 510, 1995.

75) Kojima S, Harada-Shiba M, Yamamoto A, Kojima K, Tani N: Changes of serum

amyloid proteins during LDL apheresis. Jpn J Apheresis , 14: 113-114, 1995.

76) Kojima S, Harada-Shiba M, Kuramochi M, Yamamoto A: Effect of nafamostart

mesilate on bradykinin generation and hemodynamics during LDL apheresis. Artif

Organs, 19: 135-139, 1995.

77) Harada-Shiba M, Kojima S, Touota Y, Tsushima M, Matsuoka H, Yamamoto A:

Different apheresis methods in the treatment of hypercholesterolemia in primary

biliary cirrhosis : a case report. Artif Organs, 19: 938-941, 1995.

78) Harada-Shiba M, Tajima S, Yamamoto A: Response of 3–hydoxy–3– methylglutary

1 CoA reductase to 1–triiodothyronine in cultured fibroblasts from Fh

homozygotes. Atherosclerosis, 113: 91-98, 1995.

79) Yamamoto A, Kojima S, Harada-Shiba M, Kawaguchi A, Hatanaka K: Assessment

of biocompatibility and long-term effect of LDL–apheresis by dextran sulfate –

cellulose column. Artif Organs, 16: 177-181, 1992.

80) Kojima S, Harada-Shiba M, Toyota Y, Kimura G, Tsushima M, Kuramochi M,

Sakata T, Uchida K, Yamamoto A, Omae T: Changes in coagulation factors by

passage through a dextran sulfate cellulose colmn during low-density lipoprotein

apheresis. Int J Artif Organs, 15: 185-190, 1992.

81) Harano Y, Kojima H, Kosugi K, Suzuki M, Harada-Shiba M, Nakano T, Hidaka H,

Kashiwagi A, Torii R, Taniguchi Y, Nishimori T, Yasuda Y, Shigeta Y:

Hyperlipidemia and atherosclerosis in experimental insulinopenic diabetic

monkeys. Diabetes Res Clin Prect , 16: 163-173, 1992.

82) Harada-Shiba M, Tajima S, Yokoyama S, Miyake Y, Kojima S, Tsushima M,

Kawakami M, Yamamoto A: Siblings with normal LDL reseptor activity and severe

hypercholesterolemia. Arterioscler Thromb, 12: 1071-1078, 1992.

83) Kojima S, Harada-Shiba M, Nomura S, Kimura G, Tsushima M, Kuramochi M,

Yamamoto A, Omae T: Effect of nafamostat mesilate on bradykinin generation

during low-density lipoprotein apheresis using a dextran sulfate cellulose columm.

ASAIO Trans, 37: 644-648, 1991.

84) Harada-Shiba M, Nomura S, Kojima S, Tsushima M, Kawaguchi S, Yokoyama S,

Yamamoto A: Assessment of long–term LDL apheresis in patients with severe

hypercholesterolesterolemia. ASAIO Trans, 37: 256-260, 1991.

85) Kojima S, Harada-Shiba M, Nomura S, Kimura G, Tsushima M, Yamamoto A,

Omae T: Evaluation of albumin loss during low–density lipoprotein apheresis.

ASAIO Trans, 36: 830-833, 1990.

86) Harano Y, Kojima H, Nakano T, Harada M, Kashiwagi A, Nakajima Y, Hidaka T,

Ohtsuki T, Suzuki Y, Tamura A, Fuji T, Nishimura T, Ohtaka T, Shigeta Y:

Homozygous hypobetalipoproteinemia with spared chlomicron formation.

Metabolism, 38: 1-7, 1989.

87) Tamura A, Kanda K, Fujii T, Harano Y, Harada M, Nakano T, Hidaka H, Shigeta Y,

Suzuki T, Ohtaka T: Abnormalities in the membrane of erythrocytes from two

patients homozygous for familial hypobetalipoproteinemia. J.Clin.Biochem.Nutr,

5: 103-109, 1988.

88) Harada M, Harano H, Kojima H, Suzuki M, Furusawa S, Nishino Y, Uchigaki T,

Hyodo H, Shigeta Y: Computerized glucose clamp method for the determination of

insulin sensitivity in diabetic subjects. Jpn J Med, 26: 25-30, 1987.

89) Kashiwagi A, Harano Y, Suzuki M, Kojima H, Harada M, Nishio Y, Shigeta Y:

New α2-adrenergic blocker (DG-5128) improves insulin secretion and in vivo

glucose disposal in NIDDM patients. Diabetes, 35: 1085-1089, 1986.

90) Harano Y, Ohtsuki M, Ida M, Kojima H, Harada M, Okanishi T, Kashiwagi A, Ochi

Y, Uno S, Shigeta Y: Direct automated assay Method for serum or Urine levels of

ketone bodies. Clin Chim Acta, 151: 177 – 183, 1985.

研究業績

（総説）

1) 斯波真理子: 高 LDL コレステロール血症，CURRENT THERAPY Vol.30

No.3: 33-38,2012.3

2) 斯波真理子: LDL アフェレシスの適応の是非－日本と世界の違い－, 月刊循

環器 CIRDULATION 第 2 巻 第 3 号:92-99,2012.3.

3) 岩本紀之, 斯波真理子: 脂質異常症に対するアフェレシス治療の現況, 臨牀

透析 第 27 巻 第 12 号: 23-28 (1555-1560), 2011.

4) 斯波真理子: 脂質異常症の病態と治療 家族性高コレステロール血症, 臨牀

と研究 第 88 巻 第 10 号:45-49（1263-1267）,2011.

5) 斯波真理子: 家族性高コレステロール血症の診断と治療, 日本医師会雑誌

第 140 巻 第 6 号: 1247-1250, 2011.

6) 斯波真理子: 動脈硬化症例 Q＆A 妊娠を合併した家族性高コレステロール

血症ホモ接合体例, News and Scope No.4: 9-10,2011.

7) 斯波真理子: 実地医家による診断を視野に家族性高コレステロール血症Ｇ

Ｌ作成, Medical Tribune Vol.44 No.35:27,2011.

8) 斯波真理子 : 家族性高コレステロール血症の治療指針と実態 , Medical

Tribune circulation today 2011 8 62,2011.

9) 斯波真理子: 家族性高コレステロール血症をどのように診るか？，Heart

View Vol.15 No.9:32-37,2011.

10) 斯波真理子: 家族性高コレステロール血症をどう扱うか , medicina Vol.48

No.5: 837-841, 2011.

11) 斯波真理子: 原発性高脂血症の治療, 脂質異常症診療 Q＆A: 91-98, 2011

12) 槇野久士, 斯波真理子: 脂質異常症, アフェレシスマニュアル 改訂第 3 版:

297-302, 2010.

13) 斯波真理子 : 家族性高コレステロール血症 , The Lipid Vol.21 No.4:

51-60(355-364), 2010.

14) 斯波真理子: LDL と動脈硬化―FH を中心として―, 動脈硬化予防 Vol.9

No.1: 19-27, 2010.

15) 岩本紀之, 斯波真理子: 第 16 回家族性高コレステロール血症に関する検査,

Life Style Medicine, 4(4): 361-367, 2010.

16) 斯波真理子: 家族性高コレステロール血症（FH）, 循環器病研究の進歩（通

巻 50 号） Vol.XXXI No.1: 25-33, 2010.

17) 山本剛史, 斯波真理子: LDL 受容体のあらたな制御機構と治療戦略, 医学の

あゆみ Vol.234 Nos.7,8: 754-757, 2010.

18) 斯波真理子 , 山下貴裕 : ARH と PCSK9, Medical Practice Vol.27 No.03:

494-495, 2010.

19) 山本剛史, 斯波真理子: PCSK9 阻害薬の可能性, Mebio, Vol.27 No.5: 54-62,

2010.

20) 斯波真理子 , 山下貴裕 : 家族性高コレステロール血症の治療 , Medical

Practice Vol.27 No.03: 527-532, 2010.

21) 大畑洋子, 斯波真理子: 家族性高コレステロール血症（FH,LDL 受容体遺伝

子異変）, The Lipid Vol.20 No.4: 14-19(366-371) ,2009.

22) 斯波真理子: 遺伝子異変による LDL 代謝異常―変異遺伝子の発見と装薬へ

の応用―特集にあたって, The Lipid Vol.20 No.4: 12-13(364-365), 2009.

23) 山下貴裕, 斯波真理子: 常染色体劣性遺伝性高コレステロール血症（ARH）,

The Lipid Vol.20 No.4: 20-25(372-377), 2009.

24) 鈴木朗, 斯波真理子: 高分子ナノキャリアによる遺伝子デリバリー, THE

LUNG perspectives Vol.17 No.3: 67-71(289-293), 2009.

25) 斯波真理子 : 家族性高コレステロール血症と類縁疾患 , 血管医学 Vol.10

No.1: 41-47, 2009.

26) 槙野久士, 斯波真理子: 循環器疾患に関する大規模臨床試験 脂質異常症,

Heart View Vol.13 No.4: 67-71(415-419), 2009.

27) 槙野久士, 斯波真理子: 脂質異常症, Heart View Vol.13 No.4: 67-70(415-418),

2009.

28) 杉沢貴子, 斯波真理子: トリグリセリド低下作用, 薬局 Vol.60 No.2: 55-58

(239-242),2009.

29) 杉沢貴子, 斯波真理子: 高コレステロール血症, 内科 Vol.103 No.1: 51-58,

2009.

30) 斯波真理子: 家族性高コレステロール血症はどう治療するのか？, レジデン

ト Vol.1 No.10: 62-68, 2009.

31) 斯波真理子 : 家族性高コレステロール血症 : ゲノム医学 Vol.8 No.2,

59-62(143-146), 2008-6.

32) 斯波真理子: 脂質異常症の薬物療法および非薬物療法, 呼吸と循環 第 56

巻 第 11 号 2008.11

33) 平野勉, 木庭新治, 芳野原, 田中明, 庄司哲雄, 斯波真理子, 木下誠: 家族性

複合型高脂血症の新しい診断マーカーの評価, ラボ・サービス 機器・試薬

31(3)：273～280，2008

34) 斯波真理子 : 家族性高コレステロール血症 , ゲノム医学 Vol.8 No.2

2008

35) 南雲彩子, 斯波真理子: 脂質異常症(高脂血症) LDLアフェレーシス, 最新

医学 新しい診断と治療の ABC13 2008 年発行

36) 杉沢貴子, 斯波真理子: 脂質異常症(高脂血症) 病態生理：（3）ARH,PCSK9

とリポタンパク代謝, 最新医学 新しい診断と治療の ABC13 2008

37) Makino H, Harada-Shiba M: Safety Aspects OF Statins : Which Factors Create The

Adverse Effects of Statins, Immun,Endoc,&Metab.Agents in Med.Chem,2008年 8

月発行

38) 木下誠, 芳野原, 田中朗, 庄司哲雄, 斯波真理子: small,dense LDLコレステロ

ール測定試薬を用いた家族性複合型高脂血症診断における臨床評価 , 医療

と検査機器・試薬 第 31 巻 第 2 号 200.4

39) 杉沢貴子, 斯波真理子: 家族性高コレステロール血症と類縁疾患, ホルモン

と臨床 Vol.56 №3, 2008

40) 斯波真理子: Autosomal recessive hypercholesterolemia(ARH)の 1 症例, 治

療学 Vol.41 No.9 103-106（983-986）, 2007.9

41) 斯波真理子, 槙野久士: 家族性高コレステロール血症の治療 LDL アフェ

レーシス, Medicina 第 44 巻 第 8 号 1532-1535 2007.8

42) 斯波真理子, 杉沢貴子: LDL／LDL 受容体, Medical Practice Vol.24 No.7

1173-1177, 2007

43) 斯波真理子, 南雲彩子: 脂質代謝異常―高脂血症・低脂血症―ⅠV.脂質代謝

異常の臨床 高脂血症 原発性高脂血症の病型分類と病因・臨床徴候・管理

法 原発性高コレステロール血症 家族性高コレステロール血症, 日本臨

床 65 巻増刊号 7 , 395-300, 2007.7

44) 斯波真理子, 南雲彩子: 動脈硬化の危険因子としての脂質異常症, 医学のあ

ゆみ Vol.221 No.13, 1068-1073, 2007.6

45) 斯波真理子, 杉沢貴子: 実地医家が知っておくべき基礎知識と臨床的意義

ＬＤＬ／ＬＤＬ受容体, Medical Practice Vol.24 №7 別冊 2007

46) 斯波真理子, 杉沢貴子: 常染色体劣性高コレステロール血症, 循環器病研究

の進歩 Vol.27 No.1 49-55, 2006

47) 斯波真理子: 高脂血症, スズケンファーマ Vol.9 No.2 4-6, 2006

48) 斯波真理子: 高脂血症と遺伝の関係は？高脂血症と遺伝の関係について教

えてください. 肥満と糖尿病 Vol.5 No.3: 420-421 別冊 2006

49) 斯波真理子: 生活習慣病 高脂血症. Modern Physician, Vol.26, No.5, 819-823,

2006

50) 槙野久士 , 斯波真理子 : LDL アフェレーシス -効果と限界— . The Lipid

Vol.17 No.1 2006

51) 斯波真理子: ナノテクノロジー（ナノ DDS）を用いた動脈硬化性病変の治

療・予防. 分子心血管, Vol. 7, No. 1, 2006

52) 斯波真理子: ARH ノックアウトマウス . The Lipid , Vol.16, No.4 4-10

（316-322） 2005

53) 日生下亜紀, 斯波真理子: ＬＤＬ強制除去療法とＨＤＬ－ＬＤＬ－アフェレ

ーシスにおける経験－. The Lipid, Vol.13, No.2, 35-40（169-174）, 2005

54) 斯 波 真 理 子 : 脂 質 代 謝 に お け る Autosomal Recessive

Hypercholesterolwmia(ARH)蛋白質の機能解析. 代謝異常治療研究基金研究

業績集 第 32 集 別冊 135-138､ 2005

55) 斯波真 理子 , 高木敦 子 , 横山信 治 , 山本章 : Auosomal Recessive

Hypercholesterolemia 家系の遺伝子解析. The Lipid, Vol.15 No.4, 102-103

（394-395）, 2004

56) 斯波真理子: ＡＲＨの発見とＡＲＨ蛋白の機能解析. Across, No.8, 8-13, 2004

57) 斯波真理子 , 高木敦子 , 横山信治 , 山本章 : Autosomal Recessive

Hypercholestelomia 家系の遺伝子解析. The Lipid , Vol.15 No.4 , 2004

58) 槙野久士, 斯波真理子: 代謝 1 高脂血症 ＬＤＬ－アフェレシス. 最新医

学社・別冊 新しい診断と治療の ABC13(別冊）239-246 2003

59) 斯波真理子: 高分子ナノ微粒子型遺伝子治療用ベクターの開発―ナノテク

ノロジーの医療への応用. 日本血栓止血学会誌 第 4 巻 第 6 号 2003

60) 高見澤格, 斯波真理子: スタチンの構造,活性,代謝. 治療学 Vol.36 No.5,

35-38（467-470）, 2002

61) 高見澤格, 斯波真理子: ＬＤＬとその亜分画. 日本臨床 59 巻 増刊号 2

別冊 69-74 2002

62) 斯波真理子, 片岡一則: ポリイオンコンプレックスミセル型 遺伝子治療用

ベクターの開発. Bio ベンチャー Vol.2, No.5 81-83 2002